Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.clinbiochem.2020.08.008 http://scihub22266oqcxt.onion/10.1016/j.clinbiochem.2020.08.008 32858060!7448777!32858060     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Biochem 2020 ; 86 (ä): 8-14 Nephropedia Template TP {{tp|p=32858060|t=2020. Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients |pdf=|usr=}}{{32858060}} gab.com Text Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients JO: Clin Biochem http://www.kidney.de/pget.php?&tw=1&pmid=32858060 #FOAvip OBJECTIVES: Humoral immune response to SARS-CoV-2 infection has been reported in several patient cohorts with results that vary by method and population studied due to the lack of reliable commercial assays available as the pandemic initially spread. We sought to clinically assess commercial prototype SARS-CoV-2 IgG and IgA assays for use in screening for prior infection and convalescent plasma donation. DESIGN AND METHODS: Prototype SARS-CoV-2 IgG and IgA assays from Euroimmun were assessed utilizing remnant specimens. Specificity testing used specimens in their convalescent window for the common coronaviruses and other infectious diseases known to be associated with increased non-specificity in serologic assays. Sensitivity testing utilized serial specimens from molecularly confirmed SARS-CoV-2 critically ill patients to assess seroconversion. Utilizing recombinant spike protein we also developed a competitive confirmation procedure to increase assay specificity. RESULTS: We determined specificity to be 97% and 81%, respectively, when indeterminate samples were considered positive and 99% and 86% when indeterminate samples were considered negative. We developed a new confirmation methodology to enhance the specificity of the assays with an anticipated specificity of 98% for IgA. Valuation of hospitalized COVID-19 patients determined median IgA seroconversion to be 8 days and IgG 10 days. Neither level nor timing of antibody response correlated with days on ventilation. End titer measurements indicate that validated improved assays may be capable of semi-quantitative measurement. CONCLUSIONS: We found these assays to be clinically acceptable for the high prevalence population tested, for instance, for convalescent plasma donation. Twit Text FOAVip Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients ????Clin Biochem http://www.kidney.de/pget.php?&tw=1&pmid=32858060 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32858060 #FOAvip English Wikipedia <ref>{{Cite pmid|32858060}}</ref> Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients #MMPMID32858060 Wheeler SE; Shurin GV; Keetch C; Mitchell G; Kattel G; McBreen J; Shurin MR Clin Biochem 2020[Dec]; 86 (ä): 8-14 PMID32858060show ga OBJECTIVES: Humoral immune response to SARS-CoV-2 infection has been reported in several patient cohorts with results that vary by method and population studied due to the lack of reliable commercial assays available as the pandemic initially spread. We sought to clinically assess commercial prototype SARS-CoV-2 IgG and IgA assays for use in screening for prior infection and convalescent plasma donation. DESIGN AND METHODS: Prototype SARS-CoV-2 IgG and IgA assays from Euroimmun were assessed utilizing remnant specimens. Specificity testing used specimens in their convalescent window for the common coronaviruses and other infectious diseases known to be associated with increased non-specificity in serologic assays. Sensitivity testing utilized serial specimens from molecularly confirmed SARS-CoV-2 critically ill patients to assess seroconversion. Utilizing recombinant spike protein we also developed a competitive confirmation procedure to increase assay specificity. RESULTS: We determined specificity to be 97% and 81%, respectively, when indeterminate samples were considered positive and 99% and 86% when indeterminate samples were considered negative. We developed a new confirmation methodology to enhance the specificity of the assays with an anticipated specificity of 98% for IgA. Valuation of hospitalized COVID-19 patients determined median IgA seroconversion to be 8 days and IgG 10 days. Neither level nor timing of antibody response correlated with days on ventilation. End titer measurements indicate that validated improved assays may be capable of semi-quantitative measurement. CONCLUSIONS: We found these assays to be clinically acceptable for the high prevalence population tested, for instance, for convalescent plasma donation. |*COVID-19 Serological Testing[MESH] |Antibodies, Viral/*blood[MESH] |COVID-19/*blood[MESH] |Humans[MESH] |Immunoglobulin A/*blood[MESH] |Immunoglobulin G/*blood[MESH] |Middle Aged[MESH]Evaluation of SARS-CoV-2 prototype serologic test in hospitalized pati(epmc).pdf DeepDyve Pubget Overpricing